All In Biotech

NDA 213674 · Astellas

Xtandi

Enzalutamide · Oral · Androgen Receptor Inhibitor

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Aug 4, 2020

Approved uses

4

Original approval plus efficacy supplements

Registered trials

385

74 Phase 3, 82 recruiting

FAERS reports

58,866

36,319 serious, 11,400 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 28, 2026.

XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with: • castration-resistant prostate cancer. ( 1 ) • metastatic castration-sensitive prostate cancer. ( 1 ) • non‑metastatic castration‑sensitive prostate cancer with biochemical recurrence at high risk for metastasis. ( 1 )

Mechanism: Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits nuclear translocation of androgen receptors and their interaction with DNA. A major metabolite, N‑desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro , and decreased tumor volume in a mouse prostate cancer xenograft model.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 24, 2026 Supplement 16 · Efficacy LabelLetter
  • Nov 16, 2023 Supplement 10 · Efficacy · priority review LabelLetter
  • Sep 9, 2022 Supplement 6 · Efficacy LetterLabel
  • Aug 4, 2020 Original approval · Type 3 - New Dosage Form LabelReview
2 products under this application
  • XTANDI · ENZALUTAMIDE 80MG · TABLET, ORAL · Prescription · TE AB
  • XTANDI · ENZALUTAMIDE 40MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Enzalutamide" as an intervention, any sponsor and status, largest first.

All 385 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue10,332
  • death7,715
  • malignant neoplasm progression5,499
  • prostatic specific antigen increased4,361
  • asthenia4,207
  • drug ineffective4,067
  • hot flush3,932
  • decreased appetite3,421
  • nausea3,270
  • dizziness3,172
  • diarrhoea2,813
  • back pain2,307

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2012244
20132,555
20144,441
20155,923
20167,914
201710,285
20187,756
20193,394
20202,641
20212,409
20222,608
20232,329
20242,508
20252,634
20261,225

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xtandi (Enzalutamide)

2024 spending

$3.40B

Beneficiaries

35,367

255,669 claims

Per beneficiary

$96,157

$150.09 per unit

View as table
YearSpending
2020$1,968,567,948
2021$2,411,262,130
2022$2,436,795,703
2023$2,601,510,278
2024$3,400,769,229

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 546 on PubMed

Sponsor: Astellas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.